{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:11Z","timestamp":1792790411972,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bcp.2024.116447","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T16:14:48Z","timestamp":1721492088000},"page":"116447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Hepatoprotective potential of alpha-lipoic acid against gliclazide-induced liver injury in high-glucose-exposed human liver cells and experimental type 2 diabetic rats"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-7202","authenticated-orcid":false,"given":"George J.","family":"Dugbartey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Atule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl K.","family":"Alornyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaila","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116447_b0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.me.31.020180.001401","article-title":"Efficacy and safety of oral hypoglycemic agents","volume":"31","author":"Seltzer","year":"1980","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2024.116447_b0010","first-page":"3","article-title":"Sulfonylureas: Background and development of the field","volume":"7","author":"Levine","year":"1984","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2024.116447_b0015","doi-asserted-by":"crossref","first-page":"19081","DOI":"10.3402\/jchimp.v2i3.19081","article-title":"History of current non-insulin medications for diabetes mellitus","volume":"2","author":"Quianzon","year":"2012","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"10.1016\/j.bcp.2024.116447_b0020","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.S368","article-title":"Sulfonylurea stimulation of insulin secretion","volume":"51","author":"Proks","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2024.116447_b0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.bcp.2024.116447_b0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/VHRM.S33194","article-title":"Glimepiride: Evidence-based facts, trends, and observations (GIFTS)","volume":"8","author":"Basit","year":"2012","journal-title":"Vasc. Health Risk. Manag."},{"key":"10.1016\/j.bcp.2024.116447_b0035","first-page":"54","article-title":"Sulfonylurea Review","volume":"11","author":"Yousef","year":"2018","journal-title":"Int. J. Pharm. Pharm. Res."},{"key":"10.1016\/j.bcp.2024.116447_b0040","series-title":"Medications for the Treatment of Diabetes","first-page":"5","article-title":"Overview of the medications used to treat type 2 diabetes","author":"White","year":"2008"},{"key":"10.1016\/j.bcp.2024.116447_b0045","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2174\/1573399816666200206112318","article-title":"Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications","volume":"16","author":"Vaughan","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.bcp.2024.116447_b0050","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","article-title":"Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis","volume":"56","author":"Hirst","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2024.116447_b0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijem.IJEM_556_17","article-title":"Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus\u2014International Task Force","volume":"22","author":"Kalra","year":"2018","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2024.116447_b0060","first-page":"73","article-title":"Liver disease and diabetes mellitus","volume":"17","author":"Levinthal","year":"1999","journal-title":"Clin. Diabetes."},{"key":"10.1016\/j.bcp.2024.116447_b0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.acthis.2006.03.005","article-title":"Effects of melatonin on streptozotocin-induced diabetic liver injury in rats","volume":"108","author":"Guven","year":"2006","journal-title":"Acta Histochem."},{"key":"10.1016\/j.bcp.2024.116447_b0070","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2005.02.011","article-title":"Cholestatic liver injury after glimepiride therapy","volume":"42","author":"Chounta","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2024.116447_b0075","first-page":"9251","article-title":"Glimepiride-induced cholestasis in a man with diabetes mellitus: A case Report","volume":"3","author":"Hesham","year":"2009","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.bcp.2024.116447_b0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bcp.12822","article-title":"Treatment of sulfonylurea and insulin overdose","volume":"81","author":"Klein-Schwartz","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116447_b0085","first-page":"028","article-title":"Glipizide Induced Hepatotoxicity: A Case Report and Review of Literature","volume":"6","author":"Kamal","year":"2019","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.bcp.2024.116447_b0090","first-page":"1871","article-title":"The novel effect of propranolol in glibenclamide induced hepatotoxicity","volume":"33","author":"Abrar","year":"2020","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2024.116447_b0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-200012010-00021","article-title":"Gliclazide-induced acute hepatitis","volume":"12","author":"Dourakis","year":"2000","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2024.116447_b0100","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1023\/A:1015002526879","article-title":"Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features","volume":"47","author":"Chitturi","year":"2002","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bcp.2024.116447_b0105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1620\/tjem.141.Suppl_693","article-title":"Comparison of Gliclazide and Glibenclamide Treatment in Non-Insulin-Dependent Diabetes","volume":"141","author":"Baba","year":"1983","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.bcp.2024.116447_b0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13098-018-0331-8","article-title":"Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: Analyses from the EASYDia trial","volume":"10","author":"Leiter","year":"2018","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.bcp.2024.116447_b0115","doi-asserted-by":"crossref","unstructured":"Dugbartey, G.J.; Alornyo, K.K.; N\u2019guessan, B.B.; Atule, S.; Mensah, S.D.; Adjei, S. Supplementation of conventional anti-diabetic therapy with alpha-lipoic acid prevents early development and progression of diabetic nephropathy. Biomed. Pharmacother. 2022a, 149, 112818.","DOI":"10.1016\/j.biopha.2022.112818"},{"key":"10.1016\/j.bcp.2024.116447_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.850542","article-title":"Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-\u03b2\/Smad Pathway","volume":"13","author":"Dugbartey","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116447_b0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000098953","article-title":"Alpha-lipoic acid protects against hepatic ischemia-reperfusion injury in rats","volume":"79","author":"Dulundu","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.bcp.2024.116447_b0130","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jnutbio.2014.06.001","article-title":"Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1\/LKB1\/AMPK pathway","volume":"25","author":"Yang","year":"2014","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.bcp.2024.116447_b0135","first-page":"1","article-title":"The effect of alpha-lipoic acid on liver function and metabolic markers in obese patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial","volume":"20","author":"Amirkhizi","year":"2018","journal-title":"Iran Red Crescent Med. J."},{"key":"10.1016\/j.bcp.2024.116447_b0140","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.biopha.2018.05.145","article-title":"Alpha lipoic acid exerts antioxidant effect via Nrf2\/HO-1 pathway activation and suppresses hepatic stellate cells activation induced by methotrexate in rats","volume":"105","author":"Fayez","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116447_b0145","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1039\/C9FO00449A","article-title":"Oral \u03b1-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: Effects on adipokines and liver histology features","volume":"10","author":"Rahmanabadi","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.bcp.2024.116447_b0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0960327119891212","article-title":"\u0391-Lipoic acid modulates liver fibrosis: A cross talk between TGF-\u03b21, autophagy, and apoptosis","volume":"39","author":"El-Maadawy","year":"2020","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.bcp.2024.116447_b0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13098-022-00921-x","article-title":"Targeting hepatic sulfane sulfur\/hydrogen sulfide signaling pathway with \u03b1-lipoic acid to prevent diabetes-induced liver injury via upregulating hepatic CSE\/3-MST expression","volume":"14","author":"Dugbartey","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.bcp.2024.116447_b0160","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0891-5849(97)00371-7","article-title":"Alpha-lipoic acid in liver metabolism and disease","volume":"24","author":"Bustamante","year":"1998","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2024.116447_b0165","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2337\/db08-0473","article-title":"Lipoic acid synthase (LASY): A novel role in inflammation, mitochondrial function, and insulin resistance","volume":"58","author":"Padmalayam","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2024.116447_b0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1734-1140(11)70600-4","article-title":"Lipoic acid\u2013biological activity and therapeutic potential","volume":"63","author":"Gor\u0105ca","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bcp.2024.116447_b0175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.tiv.2009.10.020","article-title":"Apoptosis in HepG2 cells exposed to high glucose","volume":"24","author":"Chandrasekaran","year":"2010","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.bcp.2024.116447_b0180","first-page":"269","article-title":"Protective effects of quercetin against hyperglycemia-induced oxidative stress in hepatic HepG2 cell line","volume":"11","author":"Yarahmadi","year":"2021","journal-title":"Avicenna J. Phytomed."},{"key":"10.1016\/j.bcp.2024.116447_b0185","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s001250100595","article-title":"Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells","volume":"44","author":"Lawrence","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2024.116447_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113386","article-title":"Activation of renal CSE\/H2S pathway by alpha-lipoic acid protects against histological and functional changes in the diabetic kidney","volume":"153","author":"Dugbartey","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116447_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115179","article-title":"Alpha-lipoic acid treatment improves adverse cardiac remodelling in the diabetic heart\u2014The role of cardiac hydrogen sulfide- synthesizing enzymes","volume":"203","author":"Dugbartey","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116447_b0200","doi-asserted-by":"crossref","first-page":"565","DOI":"10.21037\/apm.2019.11.25","article-title":"Resveratrol increase myocardial Nrf2 expression in type 2 diabetic rats and alleviate myocardial ischemia\/reperfusion injury (MIRI)","volume":"8","author":"Xu","year":"2019","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.bcp.2024.116447_b0205","first-page":"72","article-title":"Current status and prospects for quantitative analysis of digital image of pathological specimen using image processing software including artificial intelligence","volume":"2","author":"Horai","year":"2020","journal-title":"Translat. Regulat. Sci."},{"key":"10.1016\/j.bcp.2024.116447_b0210","first-page":"1233","article-title":"Acute cholestatic hepatitis induced by glimepiride","volume":"24","author":"Sitruk","year":"2000","journal-title":"Gastroenterol. Clin. Biol."},{"key":"10.1016\/j.bcp.2024.116447_b0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pdi.429","volume":"20","author":"Subramanian","year":"2003","journal-title":"Gliclazide-Induced Hepatitis. Pract. Diab. Int."},{"key":"10.1016\/j.bcp.2024.116447_b0220","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0003-4266(04)95666-1","article-title":"Glimepiride-induced cute cholestatic hepatitis","volume":"65","author":"Heurgu\u00e9","year":"2004","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.bcp.2024.116447_b0225","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1515\/jpem-2001-0814","article-title":"Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt","volume":"14","author":"Caksen","year":"2001","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2024.116447_b0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13104-018-3404-8","article-title":"Unintentional sulfonylurea toxicity due to a drug-drug interaction: A case report","volume":"11","author":"Gunaratne","year":"2018","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.bcp.2024.116447_b0235","doi-asserted-by":"crossref","first-page":"15840","DOI":"10.1016\/S0021-9258(18)47664-8","article-title":"The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells","volume":"262","author":"Schmid-Antomarchi","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116447_b0240","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2337\/diab.37.7.847","article-title":"Sulfonylurea receptors, ion channels, and fruit flies","volume":"37","author":"Boyd","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2024.116447_b0245","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1085\/jgp.201411222","article-title":"Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2\/SUR1 but not Kir6.2\/SUR2A KATP channels: A mechanistic study","volume":"144","author":"Proks","year":"2014","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.bcp.2024.116447_b0250","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/S0021-9258(18)61549-2","article-title":"3rd. Increased cytosolic calcium. A signal for sulfonylurea-stimulated insulin release from beta cells","volume":"262","author":"Nelson","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116447_b0255","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1021\/bi602547m","article-title":"Alpha-lipoic Acid as a Directly Binding Activator of the Insulin Receptor: Protection from Hepatocyte Apoptosis","volume":"46","author":"Diesel","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2024.116447_b0260","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0026-0495(97)90120-7","article-title":"Lipoic Acid Reduces Glycemia and Increases Muscle GLUT4 Content in Streptozotocin-Diabetic Rats","volume":"46","author":"Khamaisi","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.bcp.2024.116447_b0265","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbrc.2005.05.035","article-title":"Alpha-lipoic Acid Increases Insulin Sensitivity by Activating AMPK in Skeletal Muscle","volume":"332","author":"Lee","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116447_b0270","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3892\/etm.2012.601","article-title":"Protective effect of \u03b1-lipoic acid on islet cells co-cultured with 3T3L1 adipocytes","volume":"4","author":"Wang","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2024.116447_b0275","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1517\/17425255.2012.722619","article-title":"CYP2C metabolism of oral antidiabetic drugs\u2013impact on pharmacokinetics, drug interactions and pharmacogenetic aspects","volume":"8","author":"Holstein","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2024.116447_b0280","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.105.088898","article-title":"Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity","volume":"315","author":"Cover","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2024.116447_b0285","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-cellbio-100913-013226","article-title":"Regulated cell death: Signaling and mechanisms","volume":"30","author":"Ashkenazi","year":"2014","journal-title":"Ann. Rev. Cell. Dev. Biol."},{"key":"10.1016\/j.bcp.2024.116447_b0290","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/ijms18051018","article-title":"Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis","volume":"18","author":"Iorga","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116447_b0295","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.livres.2019.10.002","article-title":"Mitochondrial Damage and Biogenesis in Acetaminophen-induced Liver Injury","volume":"3","author":"Jaeschke","year":"2019","journal-title":"Liver Res."},{"key":"10.1016\/j.bcp.2024.116447_b0300","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/emboj\/17.6.1675","article-title":"Two CD95 (APO-1\/Fas) signaling pathways","volume":"17","author":"Scaffidi","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2024.116447_b0305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1478-3231.2005.01195.x","article-title":"Differential caspase-9-dependent signaling pathway between tumor necrosis factor receptor- and Fas-mediated hepatocyte apoptosis in mice","volume":"26","author":"Imao","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.bcp.2024.116447_b0310","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","article-title":"TNF-alpha induces two distinct caspase-8 activation pathways","volume":"133","author":"Wang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116447_b0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.abb.2011.12.004","article-title":"CD95 death receptor and epidermal growth factor receptor (EGFR) in liver cell apoptosis and regeneration","volume":"518","author":"Reinehr","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2024.116447_b0320","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.26547","article-title":"Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice","volume":"58","author":"Ramachandran","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2024.116447_b0325","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.fob.2014.08.007","article-title":"Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure","volume":"4","author":"Takemoto","year":"2014","journal-title":"FEBS Open Bio."},{"key":"10.1016\/j.bcp.2024.116447_b0330","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fct.2012.11.026","article-title":"The effects of alpha lipoic acid on liver cells damages and apoptosis induced by polyunsaturated fatty acids","volume":"53","author":"Kaya-Dagistanli","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bcp.2024.116447_b0335","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1464-5491.2002.00762.x","article-title":"Gliclazide improves antioxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes","volume":"19","author":"Fava","year":"2002","journal-title":"Diabet. Med."},{"key":"10.1016\/j.bcp.2024.116447_b0340","doi-asserted-by":"crossref","first-page":"203","DOI":"10.33549\/physiolres.931480","article-title":"Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet","volume":"58","author":"Sena","year":"2009","journal-title":"Physiol. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T20:46:01Z","timestamp":1723668361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224004301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":68,"alternative-id":["S0006295224004301"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116447","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatoprotective potential of alpha-lipoic acid against gliclazide-induced liver injury in high-glucose-exposed human liver cells and experimental type 2 diabetic rats","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116447"}}